Silihan lan utang jangka dawa perusahaan Amicus Pharma (FOLD)

Under the leadership of John Crowley, Amicus Therapeutics (FOLD) strives for global leadership in the therapy of rare pathologies. The company's long-term debt history, presented on GURU.Markets, where this metric equals 0.45, correlates with the implementation of revolutionary enzyme correction methods. High R&D expenditures create risks, yet success in developing unique drugs provides the company with colossal margins.

The debt_long_co metric reflects the total volume of liabilities with a maturity exceeding one year, allowing for an assessment of long-term financial stability and the cost of servicing liabilities. By analyzing the statistics of the business's long-term debt capital, an investor sees the current value of 0.45, which is critically important for Amicus Therapeutics (FOLD) amid high logistics costs and regulatory pressure in the rare disease drug segment.